StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02765997

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a myeloablative CY/FLU/TBI conditioning. A 2:1 randomization will be employed with a higher chance of being assigned to the experimental arm.

Status: 
Recruiting
Study Date: 
Wed, 06/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)